Listed

Elite Pharmaceuticals Inc

ELTPOTCCIK 1053369HealthcareFiscal year ends Mar 31

Latest reported revenue, Q1 FY2027$32.4mRevenue, Q1 FY2027, three months to 2026-06-30$32.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 13, 2026.

Latest quarter: Q1 FY2027

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$32.4mRevenue, Q1 FY2027, three months to 2026-06-30$32.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure−19.5% on a year earlier
  • Gross margin41.7%Gross margin, Q1 FY2027, three months to 2026-06-30. gross profit / revenueGross profit: $13.5m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Revenue: $32.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure−26.0 pts on a year earlier
  • Operating margin23.3%Operating margin, Q1 FY2027, three months to 2026-06-30. operating income / revenueOperating income: $7.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Revenue: $32.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure−30.7 pts on a year earlier
  • Net margin18.3%Net margin, Q1 FY2027, three months to 2026-06-30. net income / revenueNet income: $5.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Revenue: $32.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure+32.9 pts on a year earlier
  • Diluted EPS$0.01Diluted EPS, Q1 FY2027, three months to 2026-06-30$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figureSign changed from a year earlier
  • Free cash flow$9.3mFree cash flow, Q1 FY2027, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $10.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Capital expenditure: $809.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure−36.4% on a year earlier

Last eight quarters

Full statements
Revenue$32.4mGross margin 41.7%
Diluted EPS$0.01, Q1 FY2027
Free cash flow$9.3m, Q1 FY2027
Elite Pharmaceuticals Inc, key figures for the last eight quarters
Line itemUnitQ2 FY20252024-09-30Q3 FY20252024-12-31Q4 FY20252025-03-31Q1 FY20262025-06-30Q2 FY20262025-09-30Q3 FY20262025-12-31Q4 FY20262026-03-31Q1 FY20272026-06-30Shape over the periods
Revenue$m18.9Revenue, Q2 FY2025, three months to 2024-09-30$18.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure14.4Revenue, Q3 FY2025, three months to 2024-12-31$14.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure32.0Revenue, Q4 FY2025, three months to 2025-03-31$32.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Report this figure40.2Revenue, Q1 FY2026, three months to 2025-06-30$40.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure36.3Revenue, Q2 FY2026, three months to 2025-09-30$36.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure31.6Revenue, Q3 FY2026, three months to 2025-12-31$31.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure40.7Revenue, Q4 FY2026, three months to 2026-03-31$40.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Report this figure32.4Revenue, Q1 FY2027, three months to 2026-06-30$32.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure
Gross margin%43.4%Gross margin, Q2 FY2025, three months to 2024-09-30. gross profit / revenueGross profit: $8.2m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Revenue: $18.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure42.6%Gross margin, Q3 FY2025, three months to 2024-12-31. gross profit / revenueGross profit: $6.1m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Revenue: $14.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure54.1%Gross margin, Q4 FY2025, three months to 2025-03-31. gross profit / revenueGross profit: $17.3m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Revenue: $32.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Report this figure67.7%Gross margin, Q1 FY2026, three months to 2025-06-30. gross profit / revenueGross profit: $27.2m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Revenue: $40.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure38.7%Gross margin, Q2 FY2026, three months to 2025-09-30. gross profit / revenueGross profit: $14.1m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Revenue: $36.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure41.0%Gross margin, Q3 FY2026, three months to 2025-12-31. gross profit / revenueGross profit: $13.0m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Revenue: $31.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure51.0%Gross margin, Q4 FY2026, three months to 2026-03-31. gross profit / revenueGross profit: $20.8m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Revenue: $40.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Report this figure41.7%Gross margin, Q1 FY2027, three months to 2026-06-30. gross profit / revenueGross profit: $13.5m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Revenue: $32.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure
Operating margin%18.5%Operating margin, Q2 FY2025, three months to 2024-09-30. operating income / revenueOperating income: $3.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Revenue: $18.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure7.6%Operating margin, Q3 FY2025, three months to 2024-12-31. operating income / revenueOperating income: $1.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Revenue: $14.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure34.9%Operating margin, Q4 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $11.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Revenue: $32.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Report this figure54.0%Operating margin, Q1 FY2026, three months to 2025-06-30. operating income / revenueOperating income: $21.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Revenue: $40.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure22.6%Operating margin, Q2 FY2026, three months to 2025-09-30. operating income / revenueOperating income: $8.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Revenue: $36.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure28.5%Operating margin, Q3 FY2026, three months to 2025-12-31. operating income / revenueOperating income: $9.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Revenue: $31.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure25.0%Operating margin, Q4 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $10.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Revenue: $40.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Report this figure23.3%Operating margin, Q1 FY2027, three months to 2026-06-30. operating income / revenueOperating income: $7.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Revenue: $32.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure
Net margin%(58.5%)Net margin, Q2 FY2025, three months to 2024-09-30. net income / revenueNet income: −$11.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Revenue: $18.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure(75.8%)Net margin, Q3 FY2025, three months to 2024-12-31. net income / revenueNet income: −$10.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Revenue: $14.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure53.1%Net margin, Q4 FY2025, three months to 2025-03-31. net income / revenueNet income: $17.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Revenue: $32.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Report this figure(14.6%)Net margin, Q1 FY2026, three months to 2025-06-30. net income / revenueNet income: −$5.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Revenue: $40.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure37.7%Net margin, Q2 FY2026, three months to 2025-09-30. net income / revenueNet income: $13.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Revenue: $36.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure58.9%Net margin, Q3 FY2026, three months to 2025-12-31. net income / revenueNet income: $18.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Revenue: $31.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure45.3%Net margin, Q4 FY2026, three months to 2026-03-31. net income / revenueNet income: $18.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Revenue: $40.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Report this figure18.3%Net margin, Q1 FY2027, three months to 2026-06-30. net income / revenueNet income: $5.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Revenue: $32.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure
Diluted EPS$ per share(0.01)Diluted EPS, Q2 FY2025, three months to 2024-09-30−$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure(0.01)Diluted EPS, Q3 FY2025, three months to 2024-12-31−$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figurenot reported (Diluted EPS not reported)(0.01)Diluted EPS, Q1 FY2026, three months to 2025-06-30−$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure0.01Diluted EPS, Q2 FY2026, three months to 2025-09-30$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure0.01Diluted EPS, Q3 FY2026, three months to 2025-12-31$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figurenot reported (Diluted EPS not reported)0.01Diluted EPS, Q1 FY2027, three months to 2026-06-30$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure
Free cash flow$m1.4Free cash flow, Q2 FY2025, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $1.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001493152-25-023477. Derived: 6-month figure less the 3-month figure.Capital expenditure: $92.4k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-14, accession 0001493152-25-023477. Derived: 6-month figure less the 3-month figure.Report this figure(1.1)Free cash flow, Q3 FY2025, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$1.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-02-17, accession 0001493152-26-007104. Derived: 9-month figure less the 6-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-02-17, accession 0001493152-26-007104. Derived: 9-month figure less the 6-month figure.Report this figure3.2Free cash flow, Q4 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: $3.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Capital expenditure: $754.1k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Report this figure14.6Free cash flow, Q1 FY2026, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $14.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Capital expenditure: $218.2k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure5.0Free cash flow, Q2 FY2026, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $5.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001493152-25-023477. Derived: 6-month figure less the 3-month figure.Capital expenditure: $103.3k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-14, accession 0001493152-25-023477. Derived: 6-month figure less the 3-month figure.Report this figure(5.5)Free cash flow, Q3 FY2026, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$5.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-02-17, accession 0001493152-26-007104. Derived: 9-month figure less the 6-month figure.Capital expenditure: $206.1k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-02-17, accession 0001493152-26-007104. Derived: 9-month figure less the 6-month figure.Report this figure8.7Free cash flow, Q4 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $9.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Capital expenditure: $398.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Report this figure9.3Free cash flow, Q1 FY2027, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $10.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Capital expenditure: $809.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$148.9mGross margin 50.4%
Diluted EPS$0.03, FY2026
Free cash flow$22.8m, FY2026
Elite Pharmaceuticals Inc, key figures for the last five fiscal years
Line itemUnitFY20222022-03-31FY20232023-03-31FY20242024-03-31FY20252025-03-31FY20262026-03-31Shape over the periods
Revenue$m32.3Revenue, FY2022, twelve months to 2022-03-31$32.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-06-29, accession 0001493152-23-022936.Report this figure34.2Revenue, FY2023, twelve months to 2023-03-31$34.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-07-01, accession 0001493152-24-025829.Report this figure56.6Revenue, FY2024, twelve months to 2024-03-31$56.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-06-30, accession 0001641172-25-017134.Report this figure84.0Revenue, FY2025, twelve months to 2025-03-31$84.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-06-29, accession 0001493152-26-031070.Report this figure149Revenue, FY2026, twelve months to 2026-03-31$148.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-06-29, accession 0001493152-26-031070.Report this figure
Gross margin%45.9%Gross margin, FY2022, twelve months to 2022-03-31. gross profit / revenueGross profit: $14.8m. XBRL concept us-gaap:GrossProfit. 10-K filed 2023-06-29, accession 0001493152-23-022936.Revenue: $32.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-06-29, accession 0001493152-23-022936.Report this figure48.6%Gross margin, FY2023, twelve months to 2023-03-31. gross profit / revenueGross profit: $16.6m. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-07-01, accession 0001493152-24-025829.Revenue: $34.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-07-01, accession 0001493152-24-025829.Report this figure46.5%Gross margin, FY2024, twelve months to 2024-03-31. gross profit / revenueGross profit: $26.4m. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-06-30, accession 0001641172-25-017134.Revenue: $56.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-06-30, accession 0001641172-25-017134.Report this figure47.7%Gross margin, FY2025, twelve months to 2025-03-31. gross profit / revenueGross profit: $40.1m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-06-29, accession 0001493152-26-031070.Revenue: $84.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-06-29, accession 0001493152-26-031070.Report this figure50.4%Gross margin, FY2026, twelve months to 2026-03-31. gross profit / revenueGross profit: $75.0m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-06-29, accession 0001493152-26-031070.Revenue: $148.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-06-29, accession 0001493152-26-031070.Report this figure
Operating margin%15.7%Operating margin, FY2022, twelve months to 2022-03-31. operating income / revenueOperating income: $5.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-06-29, accession 0001493152-23-022936.Revenue: $32.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-06-29, accession 0001493152-23-022936.Report this figure10.8%Operating margin, FY2023, twelve months to 2023-03-31. operating income / revenueOperating income: $3.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-07-01, accession 0001493152-24-025829.Revenue: $34.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-07-01, accession 0001493152-24-025829.Report this figure19.1%Operating margin, FY2024, twelve months to 2024-03-31. operating income / revenueOperating income: $10.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-06-30, accession 0001641172-25-017134.Revenue: $56.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-06-30, accession 0001641172-25-017134.Report this figure23.3%Operating margin, FY2025, twelve months to 2025-03-31. operating income / revenueOperating income: $19.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-06-29, accession 0001493152-26-031070.Revenue: $84.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-06-29, accession 0001493152-26-031070.Report this figure33.0%Operating margin, FY2026, twelve months to 2026-03-31. operating income / revenueOperating income: $49.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-06-29, accession 0001493152-26-031070.Revenue: $148.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-06-29, accession 0001493152-26-031070.Report this figure
Net margin%27.6%Net margin, FY2022, twelve months to 2022-03-31. net income / revenueNet income: $8.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-06-29, accession 0001493152-23-022936.Revenue: $32.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-06-29, accession 0001493152-23-022936.Report this figure10.4%Net margin, FY2023, twelve months to 2023-03-31. net income / revenueNet income: $3.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-07-01, accession 0001493152-24-025829.Revenue: $34.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-07-01, accession 0001493152-24-025829.Report this figure35.5%Net margin, FY2024, twelve months to 2024-03-31. net income / revenueNet income: $20.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-06-30, accession 0001641172-25-017134.Revenue: $56.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-06-30, accession 0001641172-25-017134.Report this figure(5.1%)Net margin, FY2025, twelve months to 2025-03-31. net income / revenueNet income: −$4.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-06-29, accession 0001493152-26-031070.Revenue: $84.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-06-29, accession 0001493152-26-031070.Report this figure30.1%Net margin, FY2026, twelve months to 2026-03-31. net income / revenueNet income: $44.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-06-29, accession 0001493152-26-031070.Revenue: $148.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-06-29, accession 0001493152-26-031070.Report this figure
Diluted EPS$ per share0.01Diluted EPS, FY2022, twelve months to 2022-03-31$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-06-29, accession 0001493152-23-022936.Report this figure0.00Diluted EPS, FY2023, twelve months to 2023-03-31$0.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-07-01, accession 0001493152-24-025829.Report this figure0.02Diluted EPS, FY2024, twelve months to 2024-03-31$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-06-30, accession 0001641172-25-017134.Report this figure0.00Diluted EPS, FY2025, twelve months to 2025-03-31$0.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-06-29, accession 0001493152-26-031070.Report this figure0.03Diluted EPS, FY2026, twelve months to 2026-03-31$0.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-06-29, accession 0001493152-26-031070.Report this figure
Free cash flow$m6.0Free cash flow, FY2022, twelve months to 2022-03-31. operating cash flow − capital expenditureOperating cash flow: $6.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-06-29, accession 0001493152-23-022936.Capital expenditure: $498.6k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-06-29, accession 0001493152-23-022936.Report this figure(2.4)Free cash flow, FY2023, twelve months to 2023-03-31. operating cash flow − capital expenditureOperating cash flow: $3.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-07-01, accession 0001493152-24-025829.Capital expenditure: $5.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-07-01, accession 0001493152-24-025829.Report this figure(4.0)Free cash flow, FY2024, twelve months to 2024-03-31. operating cash flow − capital expenditureOperating cash flow: −$3.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-06-30, accession 0001641172-25-017134.Capital expenditure: $809.7k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-06-30, accession 0001641172-25-017134.Report this figure5.8Free cash flow, FY2025, twelve months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: $7.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-06-29, accession 0001493152-26-031070.Capital expenditure: $1.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-06-29, accession 0001493152-26-031070.Report this figure22.8Free cash flow, FY2026, twelve months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $23.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-06-29, accession 0001493152-26-031070.Capital expenditure: $925.6k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-06-29, accession 0001493152-26-031070.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Elite Pharmaceuticals Inc
FundQuarter endedReported valueSharesPut or callChange on the quarter before
KELLEHER FINANCIAL ADVISORS2026-06-30$3651,000Added+500

Recent filings

All 828 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Elite Pharmaceuticals Inc, recent filings
FiledFormWhat it isAccession number
2026-08-1320:17 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-26-037787
2026-08-1320:06 ET10-QQuarterly reportPeriod 2026-06-300001493152-26-037752
2026-08-1100:16 ET8-K/A7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-26-036936
2026-08-1021:07 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-26-036905
2026-08-0411:05 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-26-035922
2026-06-2920:51 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-26-031103
2026-06-2920:05 ET10-KAnnual reportPeriod 2026-03-310001493152-26-031070
2026-06-2311:02 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-26-029700
2026-06-1511:02 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-26-028610
2026-06-0111:00 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-26-026519

Latest annual report

Form 10-K for the fiscal year ended Mar 31, 2026Filed Jun 29, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q2 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1053369
Tickers
ELTP
Exchange
OTC
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Mar 31
Incorporated in
NJ
Filer category
Non-accelerated filer<br>Smaller reporting company
Former names
ELITE PHARMACEUTICALS INC /DE/ (to 2012-02-08)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:31 ET. Listed shows no prices and gives no investment advice.